Facet Life Sciences was recently featured in Life Sciences Review, spotlighting the firm’s entrepreneurial approach to FDA regulatory strategy for emerging biotechs. Life Sciences Review recently sat down with Dr. Tom Hal...
Clinical
Facet Life Sciences Appoints Frank A. Closurdo as VP, Commercial Services, Strengthening Integrated Regulatory and Market Guidance
Wayne, PA — June 2, 2026 — Facet Life Sciences, a product pathmaker for emerging biotechnology and pharmaceutical companies, today announced the appointment of Frank A. Closurdo as Vice President, Commercial Services. This addi...
Facet Life Sciences Evolves Leadership Structure to Strengthen Product Pathmaking Solutions & Deepen Partnership Value
Wayne, PA — May 13, 2026 — To support continued growth, Facet Life Sciences, a product pathmaker for emerging biotechnology, pharmaceutical, and device developers, today announced executive team changes. Facet helps lean scienc...
Facet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical Trials
Phoenixville, PA — Facet Life Sciences, a leader in regulatory strategy and drug development services, today announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the d...
Expanded Access & Compassionate Use: FDA Guidelines & Key Facts
By: Lisa VanLuvanee, Ph.D. Expanded access, also known as compassionate use, is a program that allows patients with serious or life-threatening conditions to gain access to investigational drugs, biologics, and medical devices ...
Strong Regulatory Leadership Guidance in Streamlining Product Development
In the fast-paced world of life sciences product development, regulatory submissions are not just a procedural requirement, they are a cornerstone of asset development and a requirement to getting novel and innovative products ...
gET sOCIAL